Kawasaki, Japan

Ryoto Yoshimoto

This inventor holds 1 USPTO granted patent. Top assignee: Ajinomoto Co., Ltd.. Active years: 1995.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 1995

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ryoto Yoshimoto: Innovator in Pharmaceutical Chemistry

Introduction

Ryoto Yoshimoto is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on piperidine derivatives. His research has implications for the development of hypotensive medications.

Latest Patents

Yoshimoto holds a patent for "Piperidine derivatives and hypotensives containing the same." This patent describes a piperidine compound characterized by a complex formula that includes various substituents and structural features. The compound has potential applications in the treatment of hypertension, showcasing Yoshimoto's commitment to advancing medical science.

Career Highlights

Yoshimoto is associated with Ajinomoto Co., Ltd., a leading company in the food and pharmaceutical industries. His work at Ajinomoto has allowed him to focus on innovative solutions that address health-related challenges. With a patent portfolio that includes one patent, he continues to contribute to the advancement of pharmaceutical research.

Collaborations

Throughout his career, Yoshimoto has collaborated with esteemed colleagues such as Kozo Toyota and Yoshikatsu Koyama. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Ryoto Yoshimoto's contributions to pharmaceutical chemistry, particularly through his patent on piperidine derivatives, highlight his role as an innovator in the field. His work continues to influence the development of new therapeutic options for hypertension.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…